\
&
Contact us
\
&
Contact us
Published on | 1 month ago
Programmes Agro-Food, EnvironmentThe new Bioeconomy Strategy outlines a path for building a clean and competitive economy by tapping into renewable resources from land and sea. This strategy not only aims to create jobs but also intends to position Europe as a leader in the transition to clean industries. The bioeconomy currently accounts for a value of up to €2.7 trillion in 2023 and supports approximately 17.1 million jobs in the EU.
The strategy outlines the need to scale up innovation and develop lead markets for bio-based materials by encouraging investments in sectors including agriculture, biomanufacturing, and biotechnology. The European Commission will work to create a coherent and simplified regulatory framework that rewards circular and sustainable business models, while safeguarding EU safety standards. Faster, clearer and simpler approvals for innovative solutions will support companies to develop and grow in Europe, especially for SMEs.
Interested parties are encouraged to explore the implications of the Bioeconomy Strategy. More information can be found here.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
